3 results
Approved WMOWill not start
The primary objective is to determine the pharmacokinetic characteristics of galantamine after 2 single oral doses in children with Down syndrome. Secondary objectives are to evaluate safety and tolerability.
Approved WMOCompleted
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.
Approved WMORecruiting
The objective of the clinical investigation is to evaluate the safety and performance of the Artimis* medial meniscus prosthesis system and to demonstrate that the Artimis* medial meniscus prosthesis is able to restore the function of the natural…